Pemphigus Vulgaris Clinical Trial
Official title:
A Double-Blinded, Placebo-Controlled Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris
The purpose of the study is to find out about the effectiveness and the safety of an
investigational drug called etanercept (Enbrel) to treat pemphigus vulgaris. Pemphigus
vulgaris is a potentially life threatening blistering condition that currently has no cure.
An investigational drug is one that has not been approved by the United States (US) Food and
Drug Administration (FDA) to treat a particular condition or disease. Etanercept has been
approved by the FDA to treat rheumatoid arthritis, juvenile rheumatoid arthritis, and
psoriasis, but not pemphigus vulgaris.
People with pemphigus vulgaris have been found to have an increased amount of a substance
called tumor-necrosis factor-alpha (TNF-alpha) in their blood. Etanercept may control
pemphigus vulgaris by blocking the effect of TNF-alpha. Patients diagnosed with pemphigus
vulgaris have been asked to participate in this research study.
Enrolled subjects will be given either etanercept or placebo. A placebo looks just like the
study drug but contains no active medication. Placebos help study doctors find out if the
effects of the study drug are due to the drug itself or just because of being in the study.
This type of study design helps measure the true effectiveness of a treatment. Patients have
2 chances in 3 of receiving etanercept and 1 chance in 3 of receiving placebo.
The researchers expect to enroll 24 subjects in this study. Up to 16 subjects will be
enrolled at Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH).
This study is sponsored by Amgen, Inc., the manufacturer of etanercept.
If taking part in another research study or have taken part in a research study in the last
28 days, patients will not be able to take part in this study. Patients cannot be on
multiple studies simultaneously; however, exceptions are made for non-invasive,
non-interventional, and observational studies.
This study will last about 16 weeks with a total of 6 study visits: screening, week 0
(baseline), weeks 2, 4, 8 and 16. The participants will be able to continue on your current
medications for pemphigus throughout the study.
All participants must be at least 18 years of age with a clinical diagnosis of pemphigus
vulgaris and at least 6 active blisters or erosions. Neither pregnant nor nursing women will
be included in the study.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04422912 -
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
|
Phase 1 | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Recruiting |
NCT04117529 -
Phenotypic and Functional Characterisation of Human B-cell Response in Pemphigus
|
N/A | |
Completed |
NCT03334058 -
A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus
|
Phase 2 | |
Terminated |
NCT03239470 -
Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus
|
Phase 1 | |
Completed |
NCT00606749 -
Use of KC706 for the Treatment of Pemphigus Vulgaris
|
Phase 2 | |
Terminated |
NCT00429533 -
Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris
|
Phase 2 | |
Recruiting |
NCT05594472 -
Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid
|
Phase 3 | |
Completed |
NCT02383589 -
A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)
|
Phase 3 | |
Withdrawn |
NCT03780166 -
A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris
|
Phase 2 | |
Recruiting |
NCT04096222 -
Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients
|
||
Not yet recruiting |
NCT03177213 -
Serum IL-21 Levels in Patients With Pemphigus Vulgaris
|
N/A | |
Completed |
NCT00063752 -
Safety Study of PI-0824 to Treat Pemphigus Vulgaris
|
Phase 1 | |
Terminated |
NCT03075904 -
A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
|
Phase 1/Phase 2 | |
Terminated |
NCT04598477 -
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
|
Phase 3 | |
Completed |
NCT02704429 -
A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris
|
Phase 2 | |
Completed |
NCT00626678 -
Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone
|
Phase 2 | |
Active, not recruiting |
NCT05338112 -
Role of Tzanck Smear in Determining Pemphigus Vulgaris Disease Activity
|
||
Completed |
NCT06167408 -
Identifying Factors Influencing In-Hospital Relapse in Pemphigus Patients
|
||
Recruiting |
NCT05303272 -
A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)
|
Phase 4 |